Last reviewed · How we verify
LY03003
At a glance
| Generic name | LY03003 |
|---|---|
| Also known as | rotigotine |
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD (PHASE1)
- A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD (PHASE3)
- A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro (PHASE1)
- A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients (PHASE1)
- A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003 (PHASE1)
- A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers (PHASE1)
- A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease (PHASE1)
- Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY03003 CI brief — competitive landscape report
- LY03003 updates RSS · CI watch RSS
- Luye Pharma Group Ltd. portfolio CI